Opendata, web and dolomites

BRCA-ERC SIGNED

Understanding cancer development in BRCA 1/2 mutation carriers for improved Early detection and Risk Control

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BRCA-ERC project word cloud

Explore the words cloud of the BRCA-ERC project. It provides you a very rough idea of what is the project "BRCA-ERC" about.

assembled    overtaking    surgery    epigenome    fundamental    mortality    establishing    hypothesis    ovarian    autonomous    women    placed    chronic    disease    cardiovascular    cells    neutralise    extremely    net    cancers    powerful    newly    direct    clinician    multicellular    germline    buccal    diseases    breast    outcome    efficacy    medical    distant    normal    identity    risk    mutations    carriers    lack    mechanistically    ideally    principles    epigenetic    screening    interdisciplinary    brca1    cervical    immunologists    cohort    fatal    initiating    pioneering    cancer    cell    biologists    breakthrough    samples    consequently    tissues    medicine    centered    controls    organs    reducing    reset    scientists    monitor    patient    functionalists    advocacy    blood    predictors    origin    uncover    re    trigger    core    demonstrates    preventative    scientific    recent    human    computational    groups    consequence    possibly    largely    applicable    linked    team    brca    multifactorial    mutation    effect   

Project "BRCA-ERC" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE LONDON 

Organization address
address: GOWER STREET
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 2˙497˙841 €
 EC max contribution 2˙497˙841 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-ADG
 Funding Scheme ERC-ADG
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 2˙264˙589.00
2    UNIVERSITY COLLEGE LONDON HOSPITALSNHS FOUNDATION TRUST UK (LONDON) participant 233˙251.00

Map

 Project objective

Recent evidence demonstrates that cancer is overtaking cardiovascular disease as the number one cause of mortality in Europe. This is largely due to the lack of preventative measures for common (e.g. breast) or highly fatal (e.g. ovarian) human cancers. Most cancers are multifactorial in origin. The core hypothesis of this research programme is that the extremely high risk of BRCA1/2 germline mutation carriers to develop breast and ovarian cancer is a net consequence of cell-autonomous (direct effect of BRCA mutation in cells at risk) and cell non-autonomous (produced in distant organs and affecting organs at risk) factors which both trigger epigenetic, cancer-initiating effects. The project’s aims are centered around the principles of systems medicine and built on a large cohort of BRCA mutation carriers and controls who will be offered newly established cancer screening programmes. We will uncover how ‘cell non-autonomous’ factors work, provide detail on the epigenetic changes in at-risk tissues and investigate whether these changes are mechanistically linked to cancer, study whether we can neutralise this process and measure success in the organs at risk, and ideally in easy to access samples such as blood, buccal and cervical cells. In my Department for Women’s Cancer we have assembled a powerful interdisciplinary team including computational biologists, functionalists, immunologists and clinician scientists linked to leading patient advocacy groups which is extremely well placed to lead this pioneering project to develop the fundamental understanding of cancer development in women with BRCA mutations. To reset the epigenome, re-establishing normal cell identity and consequently reducing cancer risk without the need for surgery and being able to monitor the efficacy using multicellular epigenetic outcome predictors will be a major scientific and medical breakthrough and possibly applicable to other chronic diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRCA-ERC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRCA-ERC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

THERMONANO (2018)

Nanoassemblies for the subcutaneous self-administration of anticancer drugs

Read More  

EXTREME (2020)

The Epistemology and Ethics of Fundamentalism

Read More  

iNANOVAC4CANCER (2019)

BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

Read More